Phaseline

Companies › Dr. Falk Pharma

Dr. Falk Pharma: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Gastroenterology; next expected readout Aug 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ZED1227–Phase 2Celiac DiseaseAug 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07298343ZED1227Phase 2Celiac DiseaseGastroenterologyAug 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Napo Therapeutics Panafina NorthSea Therapeutics TRYP Therapeutics Healthgen Biotechnology

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.